These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9068770)

  • 41. High vulnerability to acute dystonic reactions: a case of antipsychotic exposure and uncontrolled seizure activity.
    Coffey GL; Botts SR; de Leon J
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jun; 29(5):770-4. PubMed ID: 15927338
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: preliminary report.
    Kato D; Kawanishi C; Kishida I; Furuno T; Matsumura T; Hasegawa H; Suzuki K; Hirayasu Y
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):504-7. PubMed ID: 16048458
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.
    Rodríguez-Antona C; Gurwitz D; de Leon J; Llerena A; Kirchheiner J; de Mesa EG; Ibarreta D
    Pharmacogenomics; 2009 Apr; 10(4):685-99. PubMed ID: 19374522
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
    van der Weide K; van der Weide J
    J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CYP2D6 genotyping in patients on psychoactive drug therapy.
    Topić E; Stefanović M; Ivanisević AM; Blazinić F; Culav J; Skocilić Z
    Clin Chem Lab Med; 2000 Sep; 38(9):921-7. PubMed ID: 11097351
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia.
    Souza RP; Remington G; Meltzer HY; Lieberman JA; Kennedy JL; Wong AH
    Int Clin Psychopharmacol; 2010 Sep; 25(5):264-9. PubMed ID: 20436352
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.
    Roh HK; Chung JY; Oh DY; Park CS; Svensson JO; Dahl ML; Bertilsson L
    Br J Clin Pharmacol; 2001 Sep; 52(3):265-71. PubMed ID: 11560558
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population.
    Someya T; Suzuki Y; Shimoda K; Hirokane G; Morita S; Yokono A; Inoue Y; Takahashi S
    Psychiatry Clin Neurosci; 1999 Oct; 53(5):593-7. PubMed ID: 10595685
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment.
    van de Bilt MT; Prado CM; Ojopi EP; Sousa RT; Loch AA; Zanetti MV; Talib LL; Gattaz WF
    Schizophr Res; 2015 Oct; 168(1-2):587-8. PubMed ID: 26298540
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CYP 2D6 polymorphism and antipsychotic therapy.
    Plesnicar BK; Dolzan V; Zalar B
    Psychiatr Danub; 2008 Sep; 20(3):369-71. PubMed ID: 18827765
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of CYP2D6 variation on antipsychotic-induced hyperprolactinaemia: a systematic review and meta-analysis.
    Calafato MS; Austin-Zimmerman I; Thygesen JH; Sairam M; Metastasio A; Marston L; Abad-Santos F; Bhat A; Harju-Seppänen J; Irizar H; Zartaloudi E; Bramon E
    Pharmacogenomics J; 2020 Oct; 20(5):629-637. PubMed ID: 32015455
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study.
    Tamminga WJ; Wemer J; Oosterhuis B; de Boer A; Vranckx S; Drenth BF; de Zeeuw RA; de Leij LF; Jonkman JH
    Eur J Clin Pharmacol; 2003 May; 59(1):57-64. PubMed ID: 12743673
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation.
    Aitchison KJ; Munro J; Wright P; Smith S; Makoff AJ; Sachse C; Sham PC; Murray RM; Collier DA; Kerwin RW
    Br J Clin Pharmacol; 1999 Sep; 48(3):388-94. PubMed ID: 10510151
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
    Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
    Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis.
    Crescenti A; Mas S; Gassó P; Baiget M; Bernardo M; Lafuente A
    Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):992-7. PubMed ID: 17714084
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Study of the association between cytochromes P450 2D6 and 2E1 genotypes and the risk of drug and chemical induced idiosyncratic aplastic anaemia.
    Marsh JC; Chowdry J; Parry-Jones N; Ellis SW; Muir KR; Gordon-Smith EC; Tucker GT
    Br J Haematol; 1999 Feb; 104(2):266-70. PubMed ID: 10050706
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
    Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
    Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
    de Leon J; Susce MT; Murray-Carmichael E
    Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.
    Berecz R; de la Rubia A; Dorado P; Fernández-Salguero P; Dahl ML; LLerena A
    Eur J Clin Pharmacol; 2003 May; 59(1):45-50. PubMed ID: 12682803
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of CYP2D6 null variants among long-stay, chronic psychiatric inpatients: is it strictly necessary?
    Fernández-Santander A; Santiago C; Díez-Durán S; González M; de Castro E; Guijarro J; Bandrés F; Lucia A; Gómez-Gallego F
    Hum Psychopharmacol; 2008 Aug; 23(6):533-6. PubMed ID: 18425996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.